GSK's BCMA-directed antibody-drug conjugate Blenrep reduced the risk of death by 42% in a multiple myeloma trial that the company believes could be practice-changing. The DREAMM-7 study showed ...

The results of a phase 2 trial of MSD’s anti-ROR1 ADC zilovertamab vedotin back up the company's decision to start a phase 3 trial in DLBCL.

Untitled Boxing Game on Roblox gives you a chance to reach boxing stardom, but using codes will get you there faster.

Volcanic ash can collapse weak structures, cause power outages, and is a challenge to shovel away post-eruption. (Volcano tourism is booming, but is it too risky?) Can we predict volcanic eruptions?